Summary & Overview
AICD Lead Procedures: Inpatient Reimbursement Overview
DRG 265 covers hospital stays for insertion, revision, replacement, or repositioning of automatic implantable cardioverter-defibrillator leads and related lead procedures; it focuses on cardiac electrophysiology interventions rather than open cardiac surgery. This matters for inpatient reimbursement because Diagnosis-Related Group assignment determines Medicare payment levels by reflecting the relative resource use and clinical complexity of these procedures.
DRG 265 Overview
DRG 265 covers hospitalizations for insertion, revision, replacement, or repositioning of leads for automatic implantable cardioverter-defibrillators and related lead procedures. This Diagnosis-Related Group encompasses procedures that are primarily cardiac electrophysiology interventions rather than open cardiac surgery and often involve device- and procedure-related resource use such as operative time, imaging, and short inpatient monitoring. It matters for Medicare payment because classification into this Diagnosis-Related Group drives Medicare inpatient reimbursement based on the relative resource intensity of these lead procedures. Accurate coding of the procedure and any comorbid conditions influences case assignment and payment under the inpatient prospective payment system.
Clinical Trials
- Perioperative lead placement and fixation technique trials: studies comparing novel surgical approaches, imaging-guided lead placement, or fixation technologies in patients undergoing initial implant or lead revision for implantable cardioverter-defibrillator (ICD) systems. These trials enroll patients with ischemic or nonischemic cardiomyopathy, ventricular arrhythmias, or prior device complications, assessing acute procedural success, lead stability, pacing/sensing thresholds, and intraoperative adverse events. Results directly inform procedural best practices, reduce reoperation risk, and affect resource use and reimbursement through impacts on length of stay and complication-related costs.
- Comparative effectiveness studies of lead management strategies in complex patients: prospective observational or randomized trials comparing lead extraction versus capping and adding new leads in patients with device infection, lead malfunction, or venous occlusion, often focusing on older patients with multiple comorbidities. These studies evaluate short- and medium-term morbidity, mortality, reintervention rates, and healthcare utilization across different clinical decision pathways. Findings help clinicians and payers weigh risks, expected outcomes, and downstream expenditures associated with extraction versus conservative lead management.
- Post-discharge outcomes and remote-monitoring implementation research: cohort and implementation trials assessing remote telemetry, structured outpatient follow-up protocols, and rehabilitation pathways after AICD lead procedures to detect lead failure, arrhythmia recurrence, and device-related complications. These studies often target patients recently discharged after lead implantation or revision, including those with heart failure, to measure readmissions, emergency visits, patient-reported outcomes, and cost-effectiveness of monitoring strategies. Evidence from this area guides transitions-of-care practices, helps reduce readmission penalties, and informs payer coverage for remote monitoring services.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.